Molecular determinants of a selective matrix metalloprotease-12 inhibitor: Insights from crystallography and thermodynamic studies

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 1149-1159

  Czarny, Bertrand ^a   Stura, Enrico A ^a   Devel, Laurent ^a   Vera, Laura ^a   Cassar Lajeunesse, Evelyne ^a   Beau, Fabrice ^a   Calderone, Vito ^b   Fragai, Marco ^b   Luchinat, Claudio ^b   Dive, Vincent ^a  

^a Institute Frederic Joliot   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 12 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; ENTROPY; ENZYME ACTIVE SITE; ISOTHERMAL TITRATION CALORIMETRY; PROTON TRANSPORT; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; MATRIX METALLOPROTEINASE 12; MODELS, MOLECULAR; PROTEASE INHIBITORS; THERMODYNAMICS;

EID: 84873895441     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301574d     Document Type: Article

References (55)

1. Fanjul-Fernandez, M.; Folgueras, A. R.; Cabrera, S.; Lopez-Otin, C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models Biochim. Biophys. Acta 2010, 1803, 3-19
2. Bode, W.; Grams, F.; Reinemer, P.; Gomis-Ruth, F. X.; Baumann, U.; McKay, D. B.; Stocker, W. The metzincin superfamily of zinc peptidases Adv. Exp. Med. Biol. 1996, 389, 1-11
3. Page-McCaw, A.; Ewald, A. J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling Nature Rev. Mol. Cell. Biol. 2007, 8, 221-233
4. Parks, W. C.; Wilson, C. L.; Lopez-Boado, Y. S. Matrix metalloproteinases as modulators of inflammation and innate immunity Nature Rev. Immunol. 2004, 4, 617-629
5. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment Cell 2010, 141, 52-67
6. Rodriguez, D.; Morrison, C. J.; Overall, C. M. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics Biochim. Biophys. Acta 2010, 1803, 39-54
7. Fingleton, B. Matrix metalloproteinases as valid clinical targets Curr. Pharm. Des. 2007, 13, 333-346
8. Dejonckheere, E.; Vandenbroucke, R. E.; Libert, C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury Drug Discovery Today 2011, 16, 762-778
9. Vandenbroucke, R. E.; Dejonckheere, E.; Libert, C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur. Respir. J. 2011, 38, 1200-1214
10. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 2002, 295, 2387-2392
11. Yiotakis, A.; Dive, V. Synthetic active site-directed inhibitors of metzincins: achievement and perspectives Mol. Aspects Med. 2008, 29, 329-338
12. Devel, L.; Czarny, B.; Beau, F.; Georgiadis, D.; Stura, E.; Dive, V. Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1′ cavity Biochimie 2010, 92, 1501-1508
13. Baragi, V. M.; Becher, G.; Bendele, A. M.; Biesinger, R.; Bluhm, H.; Boer, J.; Deng, H.; Dodd, R.; Essers, M.; Feuerstein, T.; Gallagher, B. M., Jr.; Gege, C.; Hochgurtel, M.; Hofmann, M.; Jaworski, A.; Jin, L.; Kiely, A.; Korniski, B.; Kroth, H.; Nix, D.; Nolte, B.; Piecha, D.; Powers, T. S.; Richter, F.; Schneider, M.; Steeneck, C.; Sucholeiki, I.; Taveras, A.; Timmermann, A.; Van Veldhuizen, J.; Weik, J.; Wu, X.; Xia, B. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models Arthritis Rheum. 2009, 60, 2008-2018
14. Quillard, T.; Tesmenitsky, Y.; Croce, K.; Travers, R.; Shvartz, E.; Koskinas, K. C.; Sukhova, G. K.; Aikawa, E.; Aikawa, M.; Libby, P. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis Arterioscler., Thromb., Vasc. Biol. 2011, 31, 2464-2472
15. Devel, L.; Rogakos, V.; David, A.; Makaritis, A.; Beau, F.; Cuniasse, P.; Yiotakis, A.; Dive, V. Development of selective inhibitors and substrate of matrix metalloproteinase-12 J. Biol. Chem. 2006, 281, 11152-11160
16. Johnson, J. L.; Devel, L.; Czarny, B.; George, S. J.; Jackson, C. L.; Rogakos, V.; Beau, F.; Yiotakis, A.; Newby, A. C.; Dive, V. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice Arterioscler., Thromb., Vasc. Biol. 2011, 31, 528-35
17. Devel, L.; Beau, F.; Amoura, M.; Vera, L.; Cassar-Lajeunesse, E.; Garcia, S.; Czarny, B.; Stura, E. A.; Dive, V. Simple pseudo-dipeptides with a P2′ glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins J. Biol. Chem. 2012, 287, 26647-26656
18. Morales, R.; Perrier, S.; Florent, J. M.; Beltra, J.; Dufour, S.; De Mendez, I.; Manceau, P.; Tertre, A.; Moreau, F.; Compere, D.; Dublanchet, A. C.; O'Gara, M. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12 J. Mol. Biol. 2004, 341, 1063-1076
19. Dive, V.; Georgiadis, D.; Matziari, M.; Makaritis, A.; Beau, F.; Cuniasse, P.; Yiotakis, A. Phosphinic peptides as zinc metalloproteinase inhibitors Cell. Mol. Life Sci. 2004, 61, 2010-2019
20. Grams, F.; Dive, V.; Yiotakis, A.; Yiallouros, I.; Vassiliou, S.; Zwilling, R.; Bode, W.; Stocker, W. Structure of astacin with a transition-state analogue inhibitor Nature Struct. Biol. 1996, 3, 671-675
21. Junot, C.; Gonzales, M. F.; Ezan, E.; Cotton, J.; Vazeux, G.; Michaud, A.; Azizi, M.; Vassiliou, S.; Yiotakis, A.; Corvol, P.; Dive, V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis J. Pharmacol. Exp. Ther. 2001, 297, 606-611
22. Cursio, R.; Mari, B.; Louis, K.; Rostagno, P.; Saint-Paul, M. C.; Giudicelli, J.; Bottero, V.; Anglard, P.; Yiotakis, A.; Dive, V.; Gugenheim, J.; Auberger, P. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor FASEB J. 2002, 16, 93-95
23. Georgiadis, D.; Beau, F.; Czarny, B.; Cotton, J.; Yiotakis, A.; Dive, V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors Circ. Res. 2003, 93, 148-154
24. Dive, V.; Andarawewa, K. L.; Boulay, A.; Matziari, M.; Beau, F.; Guerin, E.; Rousseau, B.; Yiotakis, A.; Rio, M. C. Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases Int. J. Cancer 2005, 113, 775-781
25. Dive, V.; Cotton, J.; Yiotakis, A.; Michaud, A.; Vassiliou, S.; Jiracek, J.; Vazeux, G.; Chauvet, M. T.; Cuniasse, P.; Corvol, P. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 4330-4335
26. Jullien, N.; Makritis, A.; Georgiadis, D.; Beau, F.; Yiotakis, A.; Dive, V. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors J. Med. Chem. 2010, 53, 208-220
27. Lang, R.; Kocourek, A.; Braun, M.; Tschesche, H.; Huber, R.; Bode, W.; Maskos, K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure J. Mol. Biol. 2001, 312, 731-742
28. Bertini, I.; Calderone, V.; Cosenza, M.; Fragai, M.; Lee, Y. M.; Luchinat, C.; Mangani, S.; Terni, B.; Turano, P. Conformational variability of matrix metalloproteinases: beyond a single 3D structure Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 5334-5339
29. Bertini, I.; Calderone, V.; Fragai, M.; Giachetti, A.; Loconte, M.; Luchinat, C.; Maletta, M.; Nativi, C.; Yeo, K. J. Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases J. Am. Chem. Soc. 2007, 129, 2466-2475
30. Tochowicz, A.; Maskos, K.; Huber, R.; Oltenfreiter, R.; Dive, V.; Yiotakis, A.; Zanda, M.; Pourmotabbed, T.; Bode, W.; Goettig, P. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity J. Mol. Biol. 2007, 371, 989-1006
31. Parisini, E.; Metrangolo, P.; Pilati, T.; Resnati, G.; Terraneo, G. Halogen bonding in halocarbon-protein complexes: a structural survey Chem. Soc. Rev. 2011, 40, 2267-2278
32. Baker, B. M.; Murphy, K. P. Evaluation of linked protonation effects in protein binding reactions using isothermal titration calorimetry Biophys. J. 1996, 71, 2049-2055
33. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design Chem. Rev. 1997, 97, 1359-1472
34. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors Chem. Rev. 1999, 99, 2735-2776
35. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural basis for the highly selective inhibition of MMP-13 Chem. Biol. 2005, 12, 181-189
36. Pochetti, G.; Montanari, R.; Gege, C.; Chevrier, C.; Taveras, A. G.; Mazza, F. Extra binding region induced by non-zinc chelating inhibitors into the S1′ subsite of matrix metalloproteinase 8 (MMP-8) J. Med. Chem. 2009, 52, 1040-1049
37. Gall, A. L.; Ruff, M.; Kannan, R.; Cuniasse, P.; Yiotakis, A.; Dive, V.; Rio, M. C.; Basset, P.; Moras, D. Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state J. Mol. Biol. 2001, 307, 577-586
38. Parker, M. H.; Lunney, E. A.; Ortwine, D. F.; Pavlovsky, A. G.; Humblet, C.; Brouillette, C. G. Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry Biochemistry 1999, 38, 13592-13601
39. Ladbury, J. E.; Klebe, G.; Freire, E. Adding calorimetric data to decision making in lead discovery: a hot tip Nature Rev. Drug. Discovery 2010, 9, 23-7
40. Dabert-Gay, A. S.; Czarny, B.; Devel, L.; Beau, F.; Lajeunesse, E.; Bregant, S.; Thai, R.; Yiotakis, A.; Dive, V. Molecular determinants of matrix metalloproteinase-12 covalent modification by a photoaffinity probe: insights into activity-based probe development and conformational variability of matrix metalloproteinases J. Biol. Chem. 2008, 283, 31058-31067
41. Horovitz, A.; Levitzki, A. An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 6654-8
42. Stura, E. A.; Nemerow, G. R.; Wilson, I. A. Strategies in the Crystallization of Glycoproteins and Protein Complexes J. Cryst. Growth 1992, 122, 273-285
43. Stura, E. A.; Wilson, I. A. applications of the streak seeding technique in protein crustallization J. Cryst. Growth 1991, 110, 270-282
44. Leslie, A. G. The integration of macromolecular diffraction data Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 48-57
45. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125-132
46. Vagin, A.; Teplyakov, A. MOLEREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025
47. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
48. Collaborative Computational Project, Number 4 The CCP4 suite: Programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763
49. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501
50. Moriarty, N. W.; Grosse-Kunstleve, R. W.; Adams, P. D. Electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation Acta Crystallogr. Sect. D 2009, 65, 1074-1080
51. DeLano, W. L. The PyMOL Molecular Graphics System, L; Schrödinger LLC: New York, 2010.
52. Bermel, W.; Bertini, I.; Felli, I. C.; Lee, Y. M.; Luchinat, C.; Pierattelli, R. Protonless NMR experiments for sequence-specific assignment of backbone nuclei in unfolded proteins J. Am. Chem. Soc. 2006, 128, 3918-3919
53. Kay, L. E.; Torchia, D. A.; Bax, A. Backbone dynamics of proteins as studied by 15N inverse detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease Biochemistry 1989, 28, 8972-8979
54. 15N relaxation using inverse detected two-dimensional NMR spectroscopy: the central helix is flexible Biochemistry 1992, 31, 5269-5278
55. Peng, J. W.; Wagner, G. Investigation of protein motions via relaxation measurements Methods Enzymol. 1994, 239, 563-596